Celgene Corporation Drug Revlimid Increases Risk of Certain New Cancers

The Food and Drug Administration said certain patients treated with Celgene Corp.'s (CELG) cancer drug Revlimid have an increased risk of developing some new types of cancers. Revlimid is approved to…
Read the full story: BioSpace.com Featured News